Two multicenter, randomized, single-blind, single-dose, crossover studies of specific sensory attributes of XXXX aqueous nasal spray and @entity5023 nasal spray.

@entity1 @entity4184 @entity5023 @entity2023
BACKGROUND: Intranasal corticosteroids are effective for the treatment of @entity2023 . Sensory attributes associated with these sprays may affect @entity1 preference and adherence to treatment regimens. OBJECTIVES: These 2 studies compared @entity1 ' perceptions of and preferences for specific sensory attributes of @entity4184 aqueous nasal spray (BANS) and @entity5023 nasal spray (FPNS). METHODS: In 2 multicenter, randomized, single-blind ( @entity1 ), single-dose, 2-period, 1-day crossover studies, adults with mild to moderate @entity2023 received single doses of BANS (one 32-pg spray per nostril in both studies, 64-microg total dose) and FPNS (two 50-microg sprays per nostril in study 1, 200-pg total dose; one 50-microg spray per nostril in study 2, 100-microg total dose). Study 1 compared the once-daily recommended starting doses of BANS and FPNS, and study 2 compared BANS with half the once-daily recommended dose of FPNS to balance the number of actuations for delivery of study drug. @entity1 completed the 23-item Sensory Perceptions Questionnaire and indicated their product preference (if any). RESULTS: A total of 110 @entity1 and 71 @entity1 in study 1 and 136 @entity1 and 54 @entity1 in study 2 were randomized to treatment. None had previously used BANS or FPNS. In both studies, fewer @entity1 perceived scent or taste (both P < 0.001 in both studies), forceful spray (P < 0.001 in both studies), and a wet feel in both the nose and throat (study 1, P < 0.004; study 2, P < 0.002) with BANS than with FPNS. In addition, more @entity1 in both studies liked the spray force (study 1, P < 0.01; study 2, P < 0.001) and moisture content in the throat (study 1, P < 0.001; study 2, P < 0.006) of BANS and indicated a greater overall satisfaction with the sensory features of BANS than those of FPNS (study 1, P < 0.001; study 2, P < 0.015). In analyses that included all responding @entity1 , 54.4% of @entity1 in study 1 preferred BANS and 37.8% preferred FPNS (P < 0.022). In study 2, 47.4% preferred BANS and 41.1% preferred FPNS (not significant). Of the 92.2% of @entity1 in study 1 and 88.4% in study 2 who specified a product preference, 59.0% preferred BANS and 41.0% preferred FPNS in study 1 (P = 0.021), and 53.6% preferred BANS and 46.4% preferred FPNS in study 2 (not significant). CONCLUSIONS: On the basis of perceptions of specific sensory attributes reported after 1 administration in these 2 studies, BANS was rated as more pleasing and preferred over the recommended QD starting dose of FPNS, and was also rated as more pleasing than half the QD recommended starting dose of FPNS.
